03 febrero 2020
SMALL CELL LUNG CANCER . United Therapeutics // Unituxin .
Trial of Dinutuximab for Small Cell Lung Cancer Misses Primary Endpoint.
February 3, 2020 .
The addition of dinutuximab to irinotecan failed to extend OS among patients with relapsed or refractory small cell lung cancer, according to topline data from a randomized phase 2/phase 3 trial released by the agent’s manufacturer.
Dinutuximab (Unituxin, United Therapeutics) is a GD2-binding monoclonal antibody. It is approved in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and 13-cis-retinoic acid for treatment of pediatric patients with high-risk neuroblastoma who achieved partial response or better to first-line multiagent, multimodality therapy.
The open-label, multicenter DISTINCT study included 471 patients with relapsed or refractory small cell lung cancer treated at 198 centers in 22 countries in North America, Europe and the Asia-Pacific region.
Researchers randomly assigned patients 2:2:1 to second-line treatment with irinotecan alone (n = 190), irinotecan and dinutuximab (n = 187) or topotecan alone (n = 94).
OS in the dinutuximab-irinotecan group compared with the irinotecan monotherapy group served as the primary objective. Results showed no statistically significant OS benefit with the addition of dinutuximab.
“We thank the principal investigators, patients and their families for participating in the DISTINCT study,” Gil Golden, MD, PhD, chief medical officer of United Therapeutics, said in a company-issued press release. “We're clearly disappointed with the DISTINCT results but we’ll continue to seek out underappreciated avenues in our core therapeutic areas addressing rare diseases in oncology and pulmonary hypertension. In addition, we look forward to announcing the results of our INCREASE study by the end of the first quarter or shortly thereafter.”
Dinutuximab exhibited a safety profile consistent with that observed in prior studies.
Complete data from the DISTINCT study will be submitted for presentation at an upcoming conference and to peer-reviewed publications.
February 3, 2020 .
Dinutuximab (Unituxin, United Therapeutics) is a GD2-binding monoclonal antibody. It is approved in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and 13-cis-retinoic acid for treatment of pediatric patients with high-risk neuroblastoma who achieved partial response or better to first-line multiagent, multimodality therapy.
The open-label, multicenter DISTINCT study included 471 patients with relapsed or refractory small cell lung cancer treated at 198 centers in 22 countries in North America, Europe and the Asia-Pacific region.
Researchers randomly assigned patients 2:2:1 to second-line treatment with irinotecan alone (n = 190), irinotecan and dinutuximab (n = 187) or topotecan alone (n = 94).
OS in the dinutuximab-irinotecan group compared with the irinotecan monotherapy group served as the primary objective. Results showed no statistically significant OS benefit with the addition of dinutuximab.
“We thank the principal investigators, patients and their families for participating in the DISTINCT study,” Gil Golden, MD, PhD, chief medical officer of United Therapeutics, said in a company-issued press release. “We're clearly disappointed with the DISTINCT results but we’ll continue to seek out underappreciated avenues in our core therapeutic areas addressing rare diseases in oncology and pulmonary hypertension. In addition, we look forward to announcing the results of our INCREASE study by the end of the first quarter or shortly thereafter.”
Dinutuximab exhibited a safety profile consistent with that observed in prior studies.
Complete data from the DISTINCT study will be submitted for presentation at an upcoming conference and to peer-reviewed publications.
Pharmamar ( por técnico ) ... Aspecto Inmejorable . "Atentos a la formación de un throw back en Pharma Mar al nivel de los 4 euros ... Objetivo de la Subida : 4,50 euros .
"Atentos a la formación de un throw back en Pharma Mar al nivel de los 4 euros. Su aspecto técnico es inmejorable y sin duda es un valor que creemos que podría continuar con su escalada alcista para las próximas semanas. El objetivo de subida lo podríamos situar en los 4,50 euros", afirman los analistas técnicos de Bolsamanía.
Jazz Phamaceuticals tiene un Precio Actual de 145 ,29 $ . Analistas de EEUU le Suben el Precio Objetivo hasta los $171 con una Recomendación de Comprar ... " Gracias al Posible Potencial del Zepsyre® para el Tratamiento de SMALL CELL LUNG CANCER " .
247wallst.com / investing .
... Many investors still have not made portfolio changes since the very strong market in 2019. This is also an election year in which much is at stake, and strategists overall are calling for single-digit percentage gains in 2020.
24/7 Wall St. reviews dozens of analyst research reports each day of the week with a goal of finding new ideas for traders and long-term investors alike. Some of the daily analyst calls cover stocks to buy, while some calls cover stocks to sell or to avoid. ...
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was Reiterated as Buy and the Target Price was Raised to $171 from $166 (versus a $145.29 close) at SunTrust Robinson Humphrey.
The Firm Believes its Small-Cell Lung Cancer Could be Approved in the Second Half of this Year and that Lurbinectedin has Significant Market Potential .
24/7 Wall St. reviews dozens of analyst research reports each day of the week with a goal of finding new ideas for traders and long-term investors alike. Some of the daily analyst calls cover stocks to buy, while some calls cover stocks to sell or to avoid. ...
Coronavirus sigue sin control . China implanta más medidas para frenar una epidemia que ya ha matado a 304 personas .
ANTES EN CASA
Los ciudadanos en contacto con un infectado, internados de cuarentena
Tampoco a los fallecidos por el coronavirus o sus familiares les dejan mucha opción. Desde ayer, queda establecido que los restos del finado sean incinerados en una funeraria designada cerca de donde están, que no puedan ser trasladados entre diferentes regiones y no sean preservados por entierro u otros medios. Además, el protocolo emitido por la Comisión Nacional de Salud, el Ministerio de Asuntos Civiles y el de Seguridad Pública establecen que los cuerpos deberán ser desinfectados y colocados en una bolsa que será sellada por trabajadores médicos, tras lo cual nunca se podrá volver a abrir. ...
Coronavirus . Carrera Mundial por la Vacuna . Hay quien es muy optimista: el Shanghai East Hospital de la Universidad de Tongji (China) anunciaba esta semana que espera tenerla en 40 días.
Las graves enfermedades relacionadas con el amianto . ¿ Has podido estar expuesto ? .
La OMS estima que en el mundo aún hay unos 125 millones de personas expuestas al amianto en su lugar de trabajo, e insta a aquellos países que todavía no han tomado medidas para su total erradicación a que lo hagan sin demora.
Debido a las características de este material, duradero, anticorrosivo, resistente a las altas temperaturas y al fuego, han sido numerosas sus aplicaciones. En la construcción, en la industria del automóvil, en componentes plásticos o textiles o en el sector eléctrico, por ejemplo. Aunque cada vez en menor medida, el amianto sigue presente, en muchos casos oculto, por ejemplo como parte del aislamiento de tejados y paredes, en tuberías de canalizaciones, en antiguas turbinas o incluso en elementos fijos y móviles del transporte público. Basta recordar el plan para el desamiantado puesto en marcha por el Metro de Madrid (@metro_madrid) para eliminar la presencia de este elemento en toda su red e instalaciones.
Aunque son los trabajadores que han estado expuestos al material los más afectados, se sabe que la sustancia no solo puede resultar peligrosa en el lugar de producción, sino también en el aire cercano o en el que se respira en el interior de un edificio en el que se haya utilizado para su construcción. Incluso las minúsculas partículas que un operario haya podido llevar de su ropa hasta su hogar pueden ser un posible foco. ...